Anti-RAGE targets in cachexia: HMGB1, S100B, S100A1
Authors:
- Olga A. ObukhovaOOOlga A. Obukhova
- Irina Nikolaevna MikhailovaIMIrina Nikolaevna Mikhailova
- Helen Mykhaylovna TreshalinaHTHelen Mykhaylovna Treshalina
- Irina Vladimirovna ManinaIMIrina Vladimirovna Manina
- Irina Gennadievna MarkinaIMIrina Gennadievna Markina
- Ruslan Aleksandrovich ZukovRZRuslan Aleksandrovich Zukov
- Трещалина Елена МихайловнаТМТрещалина Елена Михайловна
Open Access
- 11 August 2023
- journal article
- review article
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (2) , 75-82
Abstract
Cachexia, mediated by the multiligand receptor RAGE (receptor for advanced glycation end products) and its ligands HMGB1, S100B, and S100A1, is a formidable multifactorial complication of the severe course of a number of somatic and malignant diseases. One of the most visualized symptoms of cachexia is a significant decrease in body weight, but the main one is the systemic shutdown of a number of regulatory centers that control the maintenance of homeostasis. Activation of these markers contributes to the launch and intensification of the destructive processes of cachexia, and blocking, in some cases, can reduce their intensity. Among known drugs from various therapeutic groups, there are blockers of one or more markers. For example, Papaverine antispasmodic as well as the nootropic anxiolytic Tenoten, antibacterial Pentamidine and antidepressant Duloxetine. This review describes in detail the significance of the listed markers in the pathogenesis of cachexia, especially in malignant pathology. An assumption was made about the possible control of cachectic progression with the help of such blockers to improve the quality of life of patients.Keywords
This publication has 46 references indexed in Scilit:
- HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNANature Communications, 2013
- Complement C3a, CpG Oligos, and DNA/C3a Complex Stimulate IFN-α Production in a Receptor for Advanced Glycation End Product-Dependent MannerThe Journal of Immunology, 2010
- Fueling inflammation at tumor microenvironment: the role of multiligand/rage axisCarcinogenesis, 2009
- Binding of S100 proteins to RAGE: An updateBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapyEuropean Journal of Cancer, 2006
- The role of calcium in hypoxia-induced signal transduction and gene expressionCell Calcium, 2004
- Amphoterin Stimulates Myogenesis and Counteracts the Antimyogenic Factors Basic Fibroblast Growth Factor and S100B via RAGE BindingMolecular and Cellular Biology, 2004
- How RAGE turns in rageGenes & Immunity, 2002
- RAGE: A Multiligand Receptor Contributing to the Cellular Response in Diabetic Vasculopathy and InflammationSeminars in Thrombosis and Hemostasis, 2000
- Molecular Cloning, Mapping to Human Chromosome 1 q21-q23, and Cell Binding Characteristics of Spα, a New Member of the Scavenger Receptor Cysteine-rich (SRCR) Family of ProteinsJournal of Biological Chemistry, 1997